Covista's $2.05B-$2.09B 2027 Target Is the Bull Case-Enrollment Is the Test

Investor Day put a number on Covista's bull case

What changed is not the story. It is the scoreboard.

At Investor Day earlier this year, Covista reaffirmed fiscal year 2026 guidance and set out financial targets for fiscal year 2027 through fiscal year 2029. That is why the setup matters now. Investors may debate whether those targets are aggressive, but they can no longer argue the bar is hidden. The company is shifting from a purpose-led narrative to an execution checklist with dates.

Why the target matters

The key question is not ambition alone. It is whether Covista already has the operating scale to support it.

Covista now serves more than 97,000 students across five accredited institutions and is supported by 385,000 alumni. That is a real platform, not a concept stage. If enrollment holds, programs stay full, and costs stay disciplined, scale can translate into operating leverage. If enrollment wobbles, the same footprint looks more like a promise than a larger business.

Enrollment is the proof point behind the revenue target

Once the 2027 target is public, the next question is mechanical: is the model still producing students at the scale revenue growth requires? The latest quarter says it is not just a plan anymore.

Covista posted total enrollment of 100,585, up 6.8% year over year, and revenue of $487.0 million, up 4.5% year over year or 8.4% adjusted for the Walden one-week academic shift. It also achieved its 11th straight quarter of growth in enrollment. For a tuition-driven business, that combination matters: enrollment is the input, and revenue follows only if students persist and complete programs.

Covista's workforce angle has real demand behind it

Covista's case rests on a simple idea: it is training people for fields where demand is genuine. The company says it graduates more than 24,000 healthcare professionals a year, more than any other educator in America, and builds its model around practice-ready graduates.

That framing also fits the broader backdrop. Covista says America faces a workforce shortage across critical sectors, including healthcare, veterinary medicine, education and business. The bull case is straightforward: if employers need more practitioners, a school system focused on those pipelines has a stronger demand base than a generic degree provider.

The latest quarter also made that case more credible. Growth was not dependent on a single school carrying the load. Chamberlain returned to positive total enrollment growth, and Walden posted 12.3% year-over-year enrollment growth. That is not proof of permanence, but it is better evidence than a one-quarter spike.

What investors need to see over the next few quarters

This is not really a debate about whether demand exists. It is a debate about whether growth is structural or simply ahead of its curve.

Why the growth case has substance

Bulls can point to three things working at the same time:

• Demand is broadening. Chamberlain returned to positive total enrollment growth instead of relying solely on Walden.
• Balance-sheet pressure does not look extreme. Covista refinanced debt to a 2033 maturity and reported 0.7x net leverage.
• The institution base is expanding. Covista now serves more than 97,000 students at five accredited institutions, giving it more capacity to compound if utilization improves.

The fresh targets also make the debate sharper. At earlier this month's Investor Day, management unveiled financial targets for fiscal year 2027 through fiscal year 2029. That turns Covista into an execution story. Investors can question the pace of growth, but they no longer have to question whether management has a public benchmark.

Where the risk still sits

Bears do not need to argue that demand is weak. Even with a workforce shortage across critical sectors, strong demand does not automatically protect pricing, mix, or retention.

The main watchpoints are:

• Whether enrollment growth broadens and holds, rather than bouncing across a few schools or programs.
• Whether revenue keeps growing at a healthy pace, including how academic-term shifts affect the reported mix.
• Whether management keeps guiding forward as it works toward the FY27 target, which would suggest the plan is still credible rather than cosmetic.

If those markers hold, Covista starts to look like durable scale. If they slip, the market may treat the targets as more ambitious than the operating proof behind them.